{
    "info": {
        "nct_id": "NCT04949113",
        "official_title": "Multicenter Phase 3 Trial Comparing Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma - NADINA",
        "inclusion_criteria": "* Men and women, at least 16 years of age;\n* World Health Organization (WHO) Performance Status 0 or 1;\n* Cytologically or histologically confirmed resectable stage III melanoma of cutaneous or unknown primary origin with one or more macroscopic lymph node metastases (clinical detectable), that can be biopsied and a maximum of 3 additional resectable in-transit metastases. A concurrent resectable primary melanoma is allowed. Clinical detectable lymph nodes are defined as either a palpable node, confirmed as melanoma by pathology, or a non-palpable but enlarged lymph node according to RECISTv1.1 (at least 15 mm in short axis), confirmed as melanoma by pathology, or a PET scan positive lymph node of any size confirmed as melanoma by pathology;\n* No other malignancies, except adequately treated and with a cancer-related life-expectancy of more than 5 years;\n* No prior immunotherapy targeting CTLA-4, PD-1 or PD-L1;\n* No prior targeted therapy targeting BRAF and/or MEK;\n* No immunosuppressive medications within 6 months prior study inclusion (steroids equivalent to prednisolone ≤10 mg are allowed);\n* Screening laboratory values must meet the following criteria: WBC ≥2.0x109/L, neutrophils ≥1.5x109/L, platelets ≥100x109/L, hemoglobin ≥5.5 mmol/L, creatinine ≤1.5xupper limit of normal (ULN), AST ≤1.5x ULN, ALT ≤1.5x ULN, bilirubin ≤1.5x ULN (except for subjects with Gilbert syndrome who must have a total bilirubin <3.0 mg/dL);\n* LDH level <1.5x ULN;\n* Women of childbearing potential (WOCP) must use appropriate method(s) of contraception, i.e. methods with a failure rate of <1% per year when used consistently and correctly, to avoid pregnancy for 23 weeks post last ipilimumab + nivolumab infusion;\n* Males who are sexually active with WOCP must use appropriate method(s) of contraception, i.e. methods with a failure rate of <1% per year when used consistently and correctly, to avoid pregnancy for 31 weeks post last ipilimumab + nivolumab infusion;\n* Patient willing and able to understand the protocol requirements and comply with the treatment schedule, scheduled visits, electronic patient outcome reporting, tumor biopsies and extra blood withdrawal during screening and in case of recurrence, and other requirements of the study;\n* Patient has signed the Informed Consent document.\nHealthy volunteers allowed\nMust have minimum age of 16 Years",
        "exclusion_criteria": "* Distantly metastasized melanoma;\n* Uveal/ocular or mucosal melanoma;\n* In-transit metastases only (without cytological or histological proven lymph node involvement)\n* Subjects with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications. Subjects with resolved childhood asthma/atopy, type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, are permitted to enroll;\n* Prior radiotherapy;\n* Subjects will be excluded if they test positive for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus ribonucleic acid (HCV antibody), indicating acute or chronic infection. Subjects treated and being at least one year free from HCV are allowed to participate;\n* Subjects will be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);\n* Subjects with history of allergy to study drug components or history of severe hypersensitivity reaction to monoclonal antibodies.\n* Subjects with underlying medical conditions or active infection that, in the investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events;\n* Women who are pregnant or breastfeeding;\n* Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids >10 mg prednisolone daily equivalent;\n* Use of other investigational drugs before study drug administration 30 days or 5 half-times before study inclusion;\n* Psychological, familial, sociological, or geographical conditions that potentially hamper compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Women of childbearing potential (WOCP) must use appropriate method(s) of contraception, i.e. methods with a failure rate of <1% per year when used consistently and correctly, to avoid pregnancy for 23 weeks post last ipilimumab + nivolumab infusion;",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (WOCP)",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must use appropriate method(s) of contraception, i.e. methods with a failure rate of <1% per year when used consistently and correctly",
                    "criterion": "contraception method",
                    "requirements": [
                        {
                            "requirement_type": "failure rate",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "% per year"
                            }
                        },
                        {
                            "requirement_type": "usage",
                            "expected_value": "consistent and correct"
                        }
                    ]
                },
                {
                    "exact_snippets": "to avoid pregnancy for 23 weeks post last ipilimumab + nivolumab infusion",
                    "criterion": "contraception duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 23,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "post last ipilimumab + nivolumab infusion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cytologically or histologically confirmed resectable stage III melanoma of cutaneous or unknown primary origin with one or more macroscopic lymph node metastases (clinical detectable), that can be biopsied and a maximum of 3 additional resectable in-transit metastases. A concurrent resectable primary melanoma is allowed. Clinical detectable lymph nodes are defined as either a palpable node, confirmed as melanoma by pathology, or a non-palpable but enlarged lymph node according to RECISTv1.1 (at least 15 mm in short axis), confirmed as melanoma by pathology, or a PET scan positive lymph node of any size confirmed as melanoma by pathology;",
            "criterions": [
                {
                    "exact_snippets": "Cytologically or histologically confirmed resectable stage III melanoma of cutaneous or unknown primary origin",
                    "criterion": "melanoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "cytological",
                                "histological"
                            ]
                        },
                        {
                            "requirement_type": "resectability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "III"
                        },
                        {
                            "requirement_type": "origin",
                            "expected_value": [
                                "cutaneous",
                                "unknown primary"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "one or more macroscopic lymph node metastases (clinical detectable)",
                    "criterion": "macroscopic lymph node metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "macroscopic lymph node metastases"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "that can be biopsied",
                    "criterion": "macroscopic lymph node metastases",
                    "requirements": [
                        {
                            "requirement_type": "biopsiable",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "a maximum of 3 additional resectable in-transit metastases",
                    "criterion": "in-transit metastases",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "in-transit metastases"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "A concurrent resectable primary melanoma is allowed",
                    "criterion": "concurrent primary melanoma",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinical detectable lymph nodes are defined as either a palpable node, confirmed as melanoma by pathology",
                    "criterion": "palpable lymph node",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathology"
                        },
                        {
                            "requirement_type": "palpability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "a non-palpable but enlarged lymph node according to RECISTv1.1 (at least 15 mm in short axis), confirmed as melanoma by pathology",
                    "criterion": "enlarged non-palpable lymph node",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 15,
                                "unit": "mm (short axis)"
                            }
                        },
                        {
                            "requirement_type": "palpability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathology"
                        }
                    ]
                },
                {
                    "exact_snippets": "a PET scan positive lymph node of any size confirmed as melanoma by pathology",
                    "criterion": "PET scan positive lymph node",
                    "requirements": [
                        {
                            "requirement_type": "PET scan positivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathology"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Screening laboratory values must meet the following criteria: WBC ≥2.0x109/L, neutrophils ≥1.5x109/L, platelets ≥100x109/L, hemoglobin ≥5.5 mmol/L, creatinine ≤1.5xupper limit of normal (ULN), AST ≤1.5x ULN, ALT ≤1.5x ULN, bilirubin ≤1.5x ULN (except for subjects with Gilbert syndrome who must have a total bilirubin <3.0 mg/dL);",
            "criterions": [
                {
                    "exact_snippets": "WBC ≥2.0x109/L",
                    "criterion": "white blood cell count (WBC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.0,
                                "unit": "x10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "neutrophils ≥1.5x109/L",
                    "criterion": "neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "x10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "platelets ≥100x109/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "hemoglobin ≥5.5 mmol/L",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5.5,
                                "unit": "mmol/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine ≤1.5xupper limit of normal (ULN)",
                    "criterion": "creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST ≤1.5x ULN",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT ≤1.5x ULN",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "bilirubin ≤1.5x ULN (except for subjects with Gilbert syndrome who must have a total bilirubin <3.0 mg/dL)",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "quantity (Gilbert syndrome exception)",
                            "expected_value": {
                                "operator": "<",
                                "value": 3.0,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No immunosuppressive medications within 6 months prior study inclusion (steroids equivalent to prednisolone ≤10 mg are allowed);",
            "criterions": [
                {
                    "exact_snippets": "No immunosuppressive medications within 6 months prior study inclusion",
                    "criterion": "immunosuppressive medication use",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to study inclusion"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "steroids equivalent to prednisolone ≤10 mg are allowed",
                    "criterion": "steroid use (prednisolone equivalent)",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg"
                            }
                        },
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Males who are sexually active with WOCP must use appropriate method(s) of contraception, i.e. methods with a failure rate of <1% per year when used consistently and correctly, to avoid pregnancy for 31 weeks post last ipilimumab + nivolumab infusion;",
            "criterions": [
                {
                    "exact_snippets": "Males who are sexually active with WOCP must use appropriate method(s) of contraception",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "methods with a failure rate of <1% per year when used consistently and correctly",
                    "criterion": "contraception method failure rate",
                    "requirements": [
                        {
                            "requirement_type": "failure rate",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "% per year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "to avoid pregnancy for 31 weeks post last ipilimumab + nivolumab infusion",
                    "criterion": "contraception duration post-treatment",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 31,
                                "unit": "weeks post last ipilimumab + nivolumab infusion"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* World Health Organization (WHO) Performance Status 0 or 1;",
            "criterions": [
                {
                    "exact_snippets": "World Health Organization (WHO) Performance Status 0 or 1",
                    "criterion": "WHO Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has signed the Informed Consent document.",
            "criterions": [
                {
                    "exact_snippets": "Patient has signed the Informed Consent document",
                    "criterion": "informed consent document",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 16 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 16 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Men and women, at least 16 years of age;",
            "criterions": [
                {
                    "exact_snippets": "Men and women",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 16 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient willing and able to understand the protocol requirements and comply with the treatment schedule, scheduled visits, electronic patient outcome reporting, tumor biopsies and extra blood withdrawal during screening and in case of recurrence, and other requirements of the study;",
            "criterions": [
                {
                    "exact_snippets": "Patient willing and able to understand the protocol requirements",
                    "criterion": "ability to understand protocol requirements",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patient willing and able to ... comply with the treatment schedule",
                    "criterion": "compliance with treatment schedule",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "comply with ... scheduled visits",
                    "criterion": "compliance with scheduled visits",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "comply with ... electronic patient outcome reporting",
                    "criterion": "compliance with electronic patient outcome reporting",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "comply with ... tumor biopsies",
                    "criterion": "compliance with tumor biopsies",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "comply with ... extra blood withdrawal during screening and in case of recurrence",
                    "criterion": "compliance with extra blood withdrawal",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "comply with ... other requirements of the study",
                    "criterion": "compliance with other study requirements",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No prior immunotherapy targeting CTLA-4, PD-1 or PD-L1;",
            "criterions": [
                {
                    "exact_snippets": "No prior immunotherapy targeting CTLA-4, PD-1 or PD-L1",
                    "criterion": "prior immunotherapy targeting CTLA-4, PD-1 or PD-L1",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No other malignancies, except adequately treated and with a cancer-related life-expectancy of more than 5 years;",
            "criterions": [
                {
                    "exact_snippets": "No other malignancies",
                    "criterion": "other malignancies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "except adequately treated",
                    "criterion": "other malignancies (adequately treated)",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "cancer-related life-expectancy of more than 5 years",
                    "criterion": "cancer-related life-expectancy (for other malignancies)",
                    "requirements": [
                        {
                            "requirement_type": "life-expectancy",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* LDH level <1.5x ULN;",
            "criterions": [
                {
                    "exact_snippets": "LDH level <1.5x ULN",
                    "criterion": "LDH level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No prior targeted therapy targeting BRAF and/or MEK;",
            "criterions": [
                {
                    "exact_snippets": "No prior targeted therapy targeting BRAF",
                    "criterion": "prior targeted therapy targeting BRAF",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "No prior targeted therapy targeting ... MEK",
                    "criterion": "prior targeted therapy targeting MEK",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Women who are pregnant or breastfeeding;",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Distantly metastasized melanoma;",
            "criterions": [
                {
                    "exact_snippets": "Distantly metastasized melanoma",
                    "criterion": "melanoma",
                    "requirements": [
                        {
                            "requirement_type": "metastasis_location",
                            "expected_value": "distant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior radiotherapy;",
            "criterions": [
                {
                    "exact_snippets": "Prior radiotherapy",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Psychological, familial, sociological, or geographical conditions that potentially hamper compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.",
            "criterions": [
                {
                    "exact_snippets": "Psychological ... conditions that potentially hamper compliance with the study protocol and follow-up schedule",
                    "criterion": "psychological conditions",
                    "requirements": [
                        {
                            "requirement_type": "potential to hamper compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "familial ... conditions that potentially hamper compliance with the study protocol and follow-up schedule",
                    "criterion": "familial conditions",
                    "requirements": [
                        {
                            "requirement_type": "potential to hamper compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "sociological ... conditions that potentially hamper compliance with the study protocol and follow-up schedule",
                    "criterion": "sociological conditions",
                    "requirements": [
                        {
                            "requirement_type": "potential to hamper compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "geographical conditions that potentially hamper compliance with the study protocol and follow-up schedule",
                    "criterion": "geographical conditions",
                    "requirements": [
                        {
                            "requirement_type": "potential to hamper compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with underlying medical conditions or active infection that, in the investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events;",
            "criterions": [
                {
                    "exact_snippets": "underlying medical conditions or active infection that, in the investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events",
                    "criterion": "underlying medical conditions",
                    "requirements": [
                        {
                            "requirement_type": "risk assessment by investigator",
                            "expected_value": "will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events"
                        }
                    ]
                },
                {
                    "exact_snippets": "underlying medical conditions or active infection that, in the investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "risk assessment by investigator",
                            "expected_value": "will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects will be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);",
            "criterions": [
                {
                    "exact_snippets": "known history of testing positive for human immunodeficiency virus (HIV)",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history of positive test",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known acquired immunodeficiency syndrome (AIDS)",
                    "criterion": "AIDS",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications. Subjects with resolved childhood asthma/atopy, type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, are permitted to enroll;",
            "criterions": [
                {
                    "exact_snippets": "any active autoimmune disease or a documented history of autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity or history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "history of syndrome that required systemic steroids or immunosuppressive medications",
                    "criterion": "syndrome requiring systemic steroids or immunosuppressive medications",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "resolved childhood asthma/atopy ... are permitted to enroll",
                    "criterion": "resolved childhood asthma/atopy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "type I diabetes mellitus ... are permitted to enroll",
                    "criterion": "type I diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement ... are permitted to enroll",
                    "criterion": "residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment ... are permitted to enroll",
                    "criterion": "skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects will be excluded if they test positive for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus ribonucleic acid (HCV antibody), indicating acute or chronic infection. Subjects treated and being at least one year free from HCV are allowed to participate;",
            "criterions": [
                {
                    "exact_snippets": "test positive for hepatitis B virus surface antigen (HBsAg)",
                    "criterion": "hepatitis B virus surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "test positive for ... hepatitis C virus ribonucleic acid (HCV antibody)",
                    "criterion": "hepatitis C virus ribonucleic acid (HCV antibody)",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects treated and being at least one year free from HCV are allowed to participate",
                    "criterion": "history of hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "treated"
                        },
                        {
                            "requirement_type": "duration free from HCV",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of other investigational drugs before study drug administration 30 days or 5 half-times before study inclusion;",
            "criterions": [
                {
                    "exact_snippets": "Use of other investigational drugs before study drug administration 30 days or 5 half-times before study inclusion",
                    "criterion": "use of other investigational drugs",
                    "requirements": [
                        {
                            "requirement_type": "time since last use before study inclusion",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 30,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-times"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uveal/ocular or mucosal melanoma;",
            "criterions": [
                {
                    "exact_snippets": "Uveal/ocular or mucosal melanoma",
                    "criterion": "melanoma subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "uveal",
                                "ocular",
                                "mucosal"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* In-transit metastases only (without cytological or histological proven lymph node involvement)",
            "criterions": [
                {
                    "exact_snippets": "In-transit metastases only",
                    "criterion": "in-transit metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exclusivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without cytological or histological proven lymph node involvement",
                    "criterion": "lymph node involvement",
                    "requirements": [
                        {
                            "requirement_type": "cytological or histological proof of involvement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids >10 mg prednisolone daily equivalent;",
            "criterions": [
                {
                    "exact_snippets": "Concurrent medical condition requiring the use of immunosuppressive medications",
                    "criterion": "concurrent medical condition requiring immunosuppressive medications",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "immunosuppressive doses of systemic or absorbable topical corticosteroids >10 mg prednisolone daily equivalent",
                    "criterion": "systemic or absorbable topical corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg prednisolone daily equivalent"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with history of allergy to study drug components or history of severe hypersensitivity reaction to monoclonal antibodies.",
            "criterions": [
                {
                    "exact_snippets": "history of allergy to study drug components",
                    "criterion": "allergy to study drug components",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of severe hypersensitivity reaction to monoclonal antibodies",
                    "criterion": "severe hypersensitivity reaction to monoclonal antibodies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}